A new simple scoring system to determine the timing and efficacy of entecavir therapy in hepatitis B-related acute-on-chronic liver failure

• Published in: Zhong hua yi xue za zhi Vol. 99; no. 4; p. 291
• Main Authors: Li, X Y, Lei, R X
• Format: Journal Article
• Language: Chinese
• Published: China 22.01.2019
• Subjects: Acute-On-Chronic Liver Failure - drug therapy; Antiviral Agents - therapeutic use; DNA, Viral; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis B; Hepatitis B virus; Humans; Treatment Outcome; Acute-on-chronic liver failure; Hepatitis B virus deoxyribonucleic acid (HBV DNA); Entecavir; Hepatitis B
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2019.04.011

To determine the timing and efficacy of entecavir (ETV) therapy in hepatitis B-related acute-on-chronic liver failure (HBV-ACLF) using a new simple scoring system. A total of 212 patients with HBV-ACLF were treated with ETV 0.5 mg daily besides the routine treatment. The severity of illness was scored by the HBV-ACLF prognostic scoring system. Hepatic failure severity scores, hepatitis B virus DNA (HBV DNA) load, and length of hospital stay were recorded at the time of initiation of treatment, and the time of survival to hospital discharge/end of life. Patiens were divided into four groups by the admission severity scores according to the percentile table: low score group (score≤ 4), medium-low score group (score: 5-7), medium-high score group (score: 8-11), and high score group (score ≥12). As the scores increased, the mortality rate increased. There were significant differences among different groups (χ(2)=310.662, 0.001). There were significant difference of the admission and discharge/death severity score